These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 34593018)

  • 61. Zoledronic acid prevents the hepatic changes associated with high fat diet in rats; the potential role of mevalonic acid pathway in nonalcoholic steatohepatitis.
    Mohamed RH; Tarek M; Hamam GG; Ezzat SF
    Eur J Pharmacol; 2019 Sep; 858():172469. PubMed ID: 31233751
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Crocin attenuates CCl
    Chhimwal J; Sharma S; Kulurkar P; Patial V
    Hum Exp Toxicol; 2020 Dec; 39(12):1639-1649. PubMed ID: 32633567
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Activation of thyroid hormone receptor-β improved disease activity and metabolism independent of body weight in a mouse model of non-alcoholic steatohepatitis and fibrosis.
    Kannt A; Wohlfart P; Madsen AN; Veidal SS; Feigh M; Schmoll D
    Br J Pharmacol; 2021 Jun; 178(12):2412-2423. PubMed ID: 33655500
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The protective effects of the β3 adrenergic receptor agonist BRL37344 against liver steatosis and inflammation in a rat model of high-fat diet-induced nonalcoholic fatty liver disease (NAFLD).
    Wang Z; Li S; Wang R; Guo L; Xu D; Zhang T; Xu Y; Wang W; Wang M; Gan Z; Wang X
    Mol Med; 2020 Jun; 26(1):54. PubMed ID: 32503411
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Mechanism of action of gypenosides on type 2 diabetes and non-alcoholic fatty liver disease in rats.
    He Q; Li JK; Li F; Li RG; Zhan GQ; Li G; Du WX; Tan HB
    World J Gastroenterol; 2015 Feb; 21(7):2058-66. PubMed ID: 25717238
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Combinations of an acetyl CoA carboxylase inhibitor with hepatic lipid modulating agents do not augment antifibrotic efficacy in preclinical models of NASH and fibrosis.
    Vijayakumar A; Okesli-Armlovich A; Wang T; Olson I; Seung M; Kusam S; Hollenback D; Mahadevan S; Marchand B; Toteva M; Breckenridge DG; Trevaskis JL; Bates J
    Hepatol Commun; 2022 Sep; 6(9):2298-2309. PubMed ID: 35735253
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Preclinical evaluation of saroglitazar magnesium, a dual PPAR-α/γ agonist for treatment of dyslipidemia and metabolic disorders.
    Patel H; Giri P; Patel P; Singh S; Gupta L; Patel U; Modi N; Shah K; Jain MR; Srinivas NR; Patel P
    Xenobiotica; 2018 Dec; 48(12):1268-1277. PubMed ID: 29224415
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Calycosin attenuates triglyceride accumulation and hepatic fibrosis in murine model of non-alcoholic steatohepatitis via activating farnesoid X receptor.
    Duan X; Meng Q; Wang C; Liu Z; Liu Q; Sun H; Sun P; Yang X; Huo X; Peng J; Liu K
    Phytomedicine; 2017 Feb; 25():83-92. PubMed ID: 28190475
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Supplementation with a Specific Combination of Metabolic Cofactors Ameliorates Non-Alcoholic Fatty Liver Disease, Hepatic Fibrosis, and Insulin Resistance in Mice.
    Quesada-Vázquez S; Colom-Pellicer M; Navarro-Masip È; Aragonès G; Del Bas JM; Caimari A; Escoté X
    Nutrients; 2021 Oct; 13(10):. PubMed ID: 34684533
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Antifibrotic Effects of 1,25(OH)
    Ma L; Ishigami M; Honda T; Yokoyama S; Yamamoto K; Ishizu Y; Kuzuya T; Hayashi K; Hirooka Y; Goto H
    Dig Dis Sci; 2019 Sep; 64(9):2581-2590. PubMed ID: 30825110
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Potential involvement of PPAR α activation in diminishing the hepatoprotective effect of fenofibrate in NAFLD: Accuracy of non- invasive panel in determining the stage of liver fibrosis in rats.
    Hamed AM; El-Kharashi OA; Boctor SS; Abd-Elaziz LF
    Biomed Pharmacother; 2017 Jan; 85():68-78. PubMed ID: 27930988
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Effect of a Dual PPAR α/γ agonist on Insulin Sensitivity in Patients of Type 2 Diabetes with Hypertriglyceridemia- Randomized double-blind placebo-controlled trial.
    Jain N; Bhansali S; Kurpad AV; Hawkins M; Sharma A; Kaur S; Rastogi A; Bhansali A
    Sci Rep; 2019 Dec; 9(1):19017. PubMed ID: 31831868
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Saroglitazar, a Dual PPAR α/γ Agonist, Improves Atherogenic Dyslipidemia in Patients With Non-Cirrhotic Nonalcoholic Fatty Liver Disease: A Pooled Analysis.
    Siddiqui MS; Parmar D; Sheikh F; Sarin SK; Cisneros L; Gawrieh S; Momin T; Duseja A; Sanyal AJ
    Clin Gastroenterol Hepatol; 2023 Sep; 21(10):2597-2605.e2. PubMed ID: 36731585
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Monascin and ankaflavin act as natural AMPK activators with PPARα agonist activity to down-regulate nonalcoholic steatohepatitis in high-fat diet-fed C57BL/6 mice.
    Hsu WH; Chen TH; Lee BH; Hsu YW; Pan TM
    Food Chem Toxicol; 2014 Feb; 64():94-103. PubMed ID: 24275089
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Danhe granule ameliorates nonalcoholic steatohepatitis and fibrosis in rats by inhibiting ceramide de novo synthesis related to CerS6 and CerK.
    Zhu M; Jia Z; Yan X; Liu L; Fang C; Feng M; Dai Y; Zhang Y; Wu H; Huang B; Li Y; Liu J; Xiao H
    J Ethnopharmacol; 2022 Sep; 295():115427. PubMed ID: 35654350
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Activation of peroxisome proliferator activated receptor alpha ameliorates ethanol induced steatohepatitis in mice.
    Kong L; Ren W; Li W; Zhao S; Mi H; Wang R; Zhang Y; Wu W; Nan Y; Yu J
    Lipids Health Dis; 2011 Dec; 10():246. PubMed ID: 22208561
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Triclosan leads to dysregulation of the metabolic regulator FGF21 exacerbating high fat diet-induced nonalcoholic fatty liver disease.
    Yueh MF; He F; Chen C; Vu C; Tripathi A; Knight R; Karin M; Chen S; Tukey RH
    Proc Natl Acad Sci U S A; 2020 Dec; 117(49):31259-31266. PubMed ID: 33229553
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Strain dependence of diet-induced NASH and liver fibrosis in obese mice is linked to diabetes and inflammatory phenotype.
    Farrell GC; Mridha AR; Yeh MM; Arsov T; Van Rooyen DM; Brooling J; Nguyen T; Heydet D; Delghingaro-Augusto V; Nolan CJ; Shackel NA; McLennan SV; Teoh NC; Larter CZ
    Liver Int; 2014 Aug; 34(7):1084-93. PubMed ID: 24107103
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Fenofibrate vs pioglitazone: Comparative study of the anti-arthritic potencies of PPAR-alpha and PPAR-gamma agonists in rat adjuvant-induced arthritis.
    Koufany M; Jouzeau JY; Moulin D
    Biomed Mater Eng; 2014; 24(1 Suppl):81-8. PubMed ID: 24928921
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Hepatoprotective effects of ZLY16, a dual peroxisome proliferator-activated receptor α/δ agonist, in rodent model of nonalcoholic steatohepatitis.
    Zhou Z; Deng L; Hu L; Ren Q; Cai Z; Wang B; Li Z; Zhang L
    Eur J Pharmacol; 2020 Sep; 882():173300. PubMed ID: 32592770
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.